Tumor testing can help determine whether certain cancers are likely to respond to immunotherapy drugs.
by Kendall K. Morgan
After adapting remote patient monitoring programs to cancer patients with COVID-19, cancer centers delve deeper into the programs’ value for cancer patients undergoing treatment.
The FDA recently expressed a new commitment to testing cancer drugs at lower doses, rather than defaulting to the highest dose most people can tolerate.
Can discussion of health inequities lead to actionable change?
Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.
AACR Dialogues showcase honest discussion about delivering equitable care.
AACR's blog writers provide coverage of the AACR Annual Meeting 2021.
While melanoma is less common than skin cancers like basal cell carcinoma or squamous cell carcinoma, it is much more deadly.
Learning Medicare’s ABCDs
donate to the AACR
The AACR Cancer Progress Report 2020, which is published annually by the American Association for Cancer Research, tracks recent developments that impact cancer care. Click “Progress Report” below to find out more.